S1:E7, Breaking Down New PAH Treatments with Dr. Hountras

In this episode of Rarely Typical, I sit down with my diagnosing doctor, Dr. Hountras, to talk about the exciting advancements in pulmonary arterial hypertension (PAH) treatments. We dive into the world of clinical trials, the importance of research, and four new drugs making waves in the PAH community: Opsynvi, Yutrepia, Seralutinib, and Sotatercept (Winrevair).

We discuss how these treatments work, who they might benefit, and why clinical trials are crucial—not just as a last resort but as a way to advance PAH care for future patients. Whether you're newly diagnosed or have been managing PAH for years, this episode is packed with valuable information on the latest treatment options.

Resources & Links

📌 Opsynvi (Macitentan/Tadalafil Combination): https://www.opsynvi.com

📌 Yutrepia (Inhaled Treprostinil): https://yutrepia.com

📌 Seralutinib (Inhaled PDGFR Inhibitor): https://www.gossamerbio.com/pipeline/seralutinib

📌 Seraluntinib PROSERA study: https://proserastudy.com/

📌 Sotatercept (Winrevair): https://www.winrevair.com

📌 Find PAH Clinical Trials: https://clinicaltrials.gov

Have thoughts on these new PAH treatments? Let’s keep the conversation going—leave a comment and follow me on social media! 💜

Disclaimer: Rarely Typical is based on my personal experiences and is not intended to be medical advice. Always consult with a qualified healthcare professional for any medical concerns or decisions.

Get full access to Rarely Typical, by Gerry Langan at itsgerrylangan.substack.com/subscribe